A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Announcing the rollout on the eve of the world’s largest cancer conference, which will take place in Chicago from Friday, NHS ...

China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...

The new "liquid biopsy" test searches for tiny fragments of DNA that are shed by tumours into the bloodstream - it can ...

The new "liquid biopsy" test searches for tiny fragments of DNA that are shed by tumours into the bloodstream.

What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

Johnson & Johnson announced today first results from the Phase 3, randomized, double-blind, placebo-controlled AMPLITUDE study evaluating the combination of niraparib and abiraterone acetate plus ...

Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...